In Latin America, the average percentage of the public budget for health is 12.75%, half of what is allocated by the 38 ...

Genetic testing company 23andMe is preparing for a renewed auction of its assets after a federal judge agreed to reopen the ...

US cardiorenal-focussed drugmaker Ardelyx (Nasdaq: ARDX) announced that Mike Kelliher, formerly executive vice president, ...

Sweden’s Sobi and US biopharma Apellis Pharmaceuticals have presented new data from the open-label period of the Phase III ...

The dynamics of the Friedreich's ataxia market are anticipated to change as companies across the globe work towards the ...

US biotech Trevi Therapeutics (Nasdaq: TRVI) has raised around $115 million in a public stock offering, giving it fresh ...

Texas-based ImmunoPrecise Antibodies (Nasdaq :IPA) a leader in AI-driven biotherapeutics, closed 22% higher Thursday. The ...

AstraZeneca (LSE: AZN) has received European approval for a fixed-duration regimen of Calquence (acalabrutinib) in ...

China-based Kelun-Biotech Biopharmaceutical (6990: HK) announced the placement of 5,918,000 H shares under its general ...

Japan’s Otsuka (TYO: 4578) today presented positive results from a pre-specified interim analysis of the Phase III VISIONARY study (NCT05248646) evaluating sibeprenlimab, for the treatment of ...

The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has authorized the use of German pharma major Bayer’s (BAYN: DE) Nubeqa (darolutamide) for the treatment of adult patients with ...

US gene therapy company RegeNXBio (Nasdaq: RGNX) yesterday announced new positive interim data from the Phase I/II AFFINITY ...